ACTIV-3/TICO, 314 patient bamlanivimab/etesevimab late treatment RCT: 100% higher mortality [p=0.22] https://c19p.org/activ3
copied to clipboard
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
LY-CoV555 study group, NEJM, doi:0.1056/NEJMoa2033130
Late stage RCT of LY-CoV555 added to remdesivir, showing non-statistically significant higher mortality with the addition of LY-CoV555. NCT04501978.Efficacy is highly variant dependent. Unlikely to be effective for omicron [Liu, Sheward, VanBlargan].
1.
Liu et al., bioRxiv, doi:10.1101/2021.12.14.472719,
Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2,
https://www.biorxiv.org/content/10.1101/2021.12.14.472719.
|
risk of death, 100% higher, HR 2.00, p = 0.22, treatment 9 of 163 (5.5%), control 5 of 151 (3.3%), adjusted per study, proportional hazards regression.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
ACTIV-3/TICO et al., 12/22/2020, Randomized Controlled Trial, USA, North America, peer-reviewed, 1 author, average treatment delay 7.0 days, trial NCT04501978.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.